Experimental Study on Alcohol Use and Behavior in Young Adults
Key facts
- Who runs it
- Karolinska Institutet
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 206 people enrolled
- Started
- 17 Oct 2023
- Ended
- 23 Apr 2025
- Type of study
- Interventional, 4 groups
- Treatments tested
- Oxytocin nasal spray
- Record updated
- 7 May 2025
- Why it stopped
- Halted due to recruitment problems.
Who can take part
- Age
- 18 years to 24 years
- Sex
- Men only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- 18-24 years of age
- Male
- Give informed consent and comply with study procedure
- Understands written Swedish; Alcohol use disorder (AUD) group
- Fulfils criteria for at least moderate AUD the past 12 months according to MINI Neuropsychiatric Interview
- Fulfils at least 8 points on the Alcohol Use Disorder Identification Test; Healthy control group
- No criteria for AUD the past 12 months according to MINI Neuropsychiatric Interview
- Fulfils less than 8 points on the Alcohol Use Disorder Identification Test
Who cannot take part
- Cannabis use on day of testing or day before testing
- Using non-prescription medicine that could not be stopped 48 hours prior to each visit
- Using intranasal medicine that could not be stopped 48 hours prior to each visit
- Fulfils criteria for any substance use disorder (except AUD for AUD-group, and mild cannabis- and nicotine use disorder for both groups)
- History of severe psychiatric disorder (e.g. severe depression, bipolar, antisocial personality disorder) or neuropsychiatric disorder of ADHD, autism or Tourette's
- Medical conditions of such severity that they require continual clinical attention, such as regular follow-up visits, prescribed medications or other specific treatment
- Allergy or intolerance to preservatives in nasal spray, e.g. latex allergy
- Upper-respiratory tract infection (i.e. a 'common cold' resulting in significant nasal congestion) at day of testing (but with the possibility of rescheduling for another time point)
- History of nasal disease (e.g. atrophic rhinitis, recurrent nose bleeds), nose damage (e.g. broken nose), and nasal surgery
- History of head trauma (i.e. loss of consciousness longer than 2 minutes)
- Using cocaine, amphetamines, hallucinogens, benzodiazepines, etc. within 1 month of the start of the study (excluding cannabis)
- Cannabis use more than 2 days in past month
- Traces of alcohol as measured by breathalyzer on the day of testing
- Prescription medicine the past 3 months
- Prescription medicine the past 3 months
- Simultaneous participation in another clinical trial
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this double blind randomized placebo-controlled clinical trial is to compare intranasal oxytocin and placebo in young adult individuals with alcohol use disorder as compared to healthy controls. The main questions it aims to answer are:
Read full original descriptionShow less
* The effect of oxytocin versus placebo on prosocial behavior in individuals with high- versus low alcohol use * The effect of oxytocin versus placebo on impulsivity, emotion recognition, social learning, and alcohol craving in individuals with high- versus low alcohol use
Participants in both groups will on two separate visits perform the following validated behavioral task measures:
* Dictator game tasks assessing prosocial behavior * Delay discounting task assessing impulsivity * Emotion recognition task assessing emotion recognition * Alcohol cue craving task assessing alcohol craving * Observational fear learning task assessing social learning
Researchers will compare groups of high and low alcohol use to see if there is a difference in effect of oxytocin versus placebo between groups.
The 4 groups in the trial
- Oxytocin/Placebo, Alcohol Use DisorderTreatment being tested
Visit 1: Alcohol Use Disorder participants will receive 24 IU of oxytocin prior to completing behavioral task measures Visit 2: Alcohol Use Disorder participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures
Treatment: Oxytocin nasal spray
- Placebo/Oxytocin, Alcohol Use DisorderTreatment being tested
Visit 1: Alcohol Use Disorder participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures Visit 2: Alcohol Use Disorder participants will receive 24 IU of oxytocin prior to completing behavioral task measures
Treatment: Oxytocin nasal spray
- Oxytocin/Placebo, Healthy ControlTreatment being tested
Visit 1: Healthy Control participants will receive 24 IU of oxytocin prior to completing behavioral task measures Visit 2: Healthy Control participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures
Treatment: Oxytocin nasal spray
- Placebo/Oxytocin, Healthy ControlTreatment being tested
Visit 1: Healthy Control participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures Visit 2: Healthy Control participants will receive 24 IU of oxytocin prior to completing behavioral task measures
Treatment: Oxytocin nasal spray
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 7 May 2025